SBRI Healthcare is one of the support offered in the Innovation Exchange – it provides funds and targeted support for early stage companies and has a portfolio of over 150 companies developing solutions for healthcare needs.
In this session, Karen Livingstone, National Director of the Innovation Exchange and SBRI Healthcare will outline how you can register with your innovation exchange, secure the assistance of the AHSNs and potentially secure funding and resources through SBRI healthcare.
This presentation will give an overview of the growth of the use of 3D printing in the manufacture of medical devices, and the potential for bioprinting in the generation of combination products.
3D printing now has a 20 year track record of use in the manufacture of medical devices, and the presentation will review how applications have grown through application in teeth aligners, surgical guides, hearing aids and orthotics and prosthetics, and how the understanding and regulation of these products has matured over that time, and the outlook for future applications.
Bioprinting technologies are now emerging, and share much basic technology with 3D printing, and so working from the understanding gained from 3D printing’s history the presentation will explore how bioprinting could be used to enhance medical devices, generating combination products with enhanced functionality.
Innovate UK is the UK’s Innovation Agency and the prime channel by which UK Government incentivises innovation in businesses. It is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. We drive productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK’s world-class research base.
The life science industry forms a strong part of the Innovate UK portfolio. Med tech businesses contribute significantly to UK economic growth in terms of turnover and employment and Innovate UK has grown the UK’s best medtech businesses through a range of initiatives.
In this session you will hear about success stories from the med tech sector and current opportunities for Innovate UK support.
Since 2010, Device Access UK, a division of the IGES Institut GmbH, has been assisting global MedTech companies access the NHS. They have a particular focus on gaining NICE approvals and have helped 30 companies go through formal NICE assessments. They provide a suite of supporting services, including analysis of current NHS Patient pathways through their licence with NHS Digital, Health Economics and publications, NHS Busines Case dossiers and procedure reimbursement.
Michael will explain the Principles of Successful Market Access through strategies around how to demonstrate benefits to patients, providers of care, payers of care and the ability to optimise selling price, whilst maximising the technologies available to the most relevant patients.
The medical device industry brings many innovative and iterative products to the healthcare market every year. How do the changing needs and demands of clinicians, patients, managers and policy-makers influence product design and how has this changed over the years? From the early days of the modern industry to some of the driving principles that impact development and design today.
What changes can we anticipate in the near future?
Increasingly the device industry has diversified into service provision. How do these services incorporate the perspective of the patient and bring greater efficiency?
How is demand stimulated and who is the real customer? Is industry responding in the right way or is there still a long way to go?
The behaviours and incentives in different health systems need to be considered in product and service development. At the same time the market is increasingly globalised. Can such diversity be incorporated at an affordable cost? How does the industry generate the data to demonstrate value & benefit – how is this designed in to evidence programmes?
Current healthcare systems are no longer sustainable. Across the world we see an increasing gap between the demand and ability to pay for healthcare, which is leading to huge inequalities. Healthcare technologies are the key driver of growing healthcare costs. Currently research institutes and established MedTech industry focus on high-tech that requires huge investments and long development times; the end-products are so complex that their operation require highly trained and specialised clinicians.
Disruptive innovation provides an opportunity to break through this vicious cycle by developing products based on simplifying technologies, that are affordable, do not require extensive training and can be used by GPs, nurses or patients themselves. It has been demonstrated that disruptive innovation is the domain of start-ups and agile SMEs; not of the incumbents. But maximising this opportunity requires understanding the theory and the practical implications of disruptive innovation.
The presentation will: demonstrate the urgent need for disruptive innovation in healthcare; present some examples and explore what is required for business to use it and patients to benefit.
Over 70% of clinical decisions are made by using Diagnostics. IVDs have a vital part to play in creating an efficient and sustainable Healthcare system but IVDs only account for >2% of the Health care system spend frequently being seen as a “cost” rather than credited for the “value” they bring. Often IVDs are referred to as the “silent champions” of healthcare. What is “value” is and what does it mean for the different parts of the health system and patients?
There are many challenges faced in the development and commercialisation of IVD innovations in the UK. Developing a new innovation is not the hardest part of the journey. The toughest part of the journey is obtaining the “access” and then the “adoption” by the NHS which often forces many Small and Medium Enterprises (SMEs) to develop their products in the UK but to commercialise them first outside of the UK.
Recognising the issue, Government has focused its efforts in addressing these challenges with some key initiatives such as the Life Sciences Industrial Strategy (LSIS) and the Industrial Strategy Challenge Fund (ISCF). In addition, the AAC and RUP are designed to “fast track” the adoption of innovations in the health system for the benefit of all. How well are these new mechanisms working?
Healthcare organisations and systems globally are facing unique pressures, many of which are strategic in nature. This session will outline the imperative for healthcare leaders to take an ecosystem approach in seeking to develop their strategy and in enabling new forms of value and innovation. Whilst health organisations currently are overly focused on activities within their own organisational boundaries, this talk will suggest that new forms of value and new types of services cannot be delivered in isolation. Rather they require strategic partnerships and new business models that are enhanced when taking an ecosystem approach.
The presentation will focus on three areas; namely, what is an ecosystem, how can new forms of value be developed in ecosystems, and how is leadership exercised across ecosystem
A great place to engage with innovators and stakeholders across the innovation landscape.
A well organised exhibition that generated plenty of foot fall. We would happily support Med-Tech Innovation Expo again, and look forward to the relocation to the NEC.
We met several companies who gave us interesting and knowledgeable information which will assist us in our future product and manufacturing decisions.
Great show for presenting our company to the medical device marketplace we had plenty of interesting conversations which am i sure will convert into business opportunities.